Doctors warn of hidden threat of COVID-19 involving Portal Vein Thrombosis

Medical News: Study sheds light on the link between COVID-19 and a rare but dangerous condition.
COVID-19 has changed our understanding of how viruses affect the human body. While many people are aware of its impact on the respiratory system, the virus can also cause serious complications in other areas, such as the cardiovascular and digestive systems. One of these complications is portal vein thrombosis (PVT), a condition where a blood clot forms in the portal vein, which transports blood from the digestive organs to the liver.


Doctors warn of hidden threat of COVID-19 involving Portal Vein Thrombosis

A recent study, conducted by researchers from Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta Hierro-Segovia Arana (IDIPHISA), and the Centro de Investigación Biomédica en Red (CIBEREHD), all based in Madrid, Spain, aimed to assess the prevalence of PVT in COVID-19 patients. This Medical News report will explore their key findings and what they mean for patients and healthcare providers.
 
COVID-19 and Blood Clots: An Emerging Threat
COVID-19 is notorious for its prothrombotic effects, meaning it increases the risk of blood clots. These clots can occur in various parts of the body, such as the legs (deep vein thrombosis) or lungs (pulmonary embolism). However, its role in causing clots in the portal vein has been less explored.
 
This study focused on identifying cases of PVT in COVID-19 patients, a condition that can lead to severe consequences like intestinal ischemia, where parts of the intestine lose blood supply, potentially causing tissue death. The study included 60 patients who had tested positive for COVID-19 between March and June 2020 and underwent abdominal CT scans within six months of their diagnosis. Out of these 60 patients, three (or 5%) were found to have PVT, which could suggest a greater risk of the condition in COVID-19 patients than previously thought.
 
The Study: Examining the Data
The researchers specifically chose patients who had undergone abdominal CT scans after their COVID-19 diagnosis. This method allowed them to identify cases of PVT that might have gone undiagnosed otherwise. Patients with a history of splanchnic vein thrombosis (blood clots in the veins that serve the abdominal organs) were excluded, ensuring that any PVT found was likely related to the recent COVID-19 infection.
 
The study’s results showed that three out of 60 patients had PVT. All three patients were men, and their ages ranged from 34 to 62 years. Two of these patients had no pre-existing conditions that would typically increase the risk of PVT, such as liver cirrhosis, while the third patient did have cirrhosis. Interestingly, all three patients were treated with anticoagulants (blood-thinning medications), and all achieved full recovery, with no long-term complications during a follow-up period of more than two years.
 
In addition to PVT, the study also found other thromboembolic events in the patients. Six had pul monary embolisms, and three had deep vein thrombosis, further confirming the prothrombotic nature of COVID-19.
 
A Closer Look at Portal Vein Thrombosis
PVT is a rare condition, especially in the absence of liver disease. In most cases, the condition is asymptomatic, meaning people do not experience any symptoms until complications arise. For those with symptoms, abdominal pain is the most common complaint, particularly in cases without underlying cirrhosis. Ascites, or the accumulation of fluid in the abdomen, can also occur, particularly in patients with cirrhosis.
 
The time between the onset of COVID-19 symptoms and the diagnosis of PVT varied among the three patients in the study, ranging from 10 to 21 days. This suggests that PVT may not be an immediate complication of COVID-19 but could develop in the weeks following the initial infection.
 
What Causes PVT in COVID-19 Patients?
The exact mechanisms by which COVID-19 causes PVT are still not fully understood. However, it is known that the virus can cause widespread inflammation and damage to blood vessels, which increases the risk of clot formation. Specifically, COVID-19 may damage the lining of the blood vessels (endothelial cells), leading to a state of hypercoagulability, where the blood is more likely to clot.
 
The study team suggests that the damage caused by the virus, combined with the body’s inflammatory response, creates the perfect storm for clot formation. This is particularly concerning in the portal vein, as a clot in this area can rapidly expand to other parts of the venous system, leading to life-threatening complications such as intestinal ischemia.
 
Key Study Findings
-Prevalence: Out of 60 COVID-19 patients who underwent abdominal CT scans, 5% were diagnosed with PVT.
 
-Patient Demographics: All patients with PVT were male, and their ages ranged from 34 to 62 years.
 
-Treatment and Outcomes: All three patients received anticoagulant therapy, which successfully cleared the clots, and none experienced long-term complications.
 
-Related Complications: In addition to PVT, other thromboembolic events such as pulmonary embolism and deep vein thrombosis were observed, reinforcing the connection between COVID-19 and blood clots.
 
The Importance of Early Detection and Treatment
One of the most important takeaways from this study is the need for early detection and treatment of PVT in COVID-19 patients. Since the condition can often be asymptomatic, it may go undiagnosed until complications arise. However, if detected early, PVT can be effectively treated with anticoagulants, as shown in this study.
 
The researchers emphasize the need for healthcare providers to be aware of the risk of PVT in COVID-19 patients, particularly those who are hospitalized or have other risk factors for blood clots. Routine screening for PVT in COVID-19 patients may not be feasible, but providers should be vigilant for symptoms such as unexplained abdominal pain or swelling.
 
Conclusions
This study highlights an important but under-recognized complication of COVID-19: portal vein thrombosis. While rare, the condition can have serious consequences if left untreated. The findings of this study suggest that COVID-19 patients, especially those with severe disease or other thromboembolic conditions, may be at increased risk for PVT.
 
Early detection and treatment with anticoagulants can lead to positive outcomes, as demonstrated by the three patients in this study, all of whom recovered fully without long-term complications. However, more research is needed to fully understand the relationship between COVID-19 and PVT and to develop strategies for identifying and treating this condition before it leads to severe complications.
As the world continues to grapple with the long-term effects of the COVID-19 pandemic, it is important to remain aware of the various ways the virus can impact the body, including its role in increasing the risk of blood clots like PVT.
 
The study findings were published in the peer-reviewed Journal of Clinical Medicine.
https://www.mdpi.com/2077-0383/13/18/5599
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/unveiling-the-uniqueness-of-covid-19-induced-thrombosis
 
https://www.thailandmedical.news/news/covid-19-news-study-uncovers-the-role-of-anti-phospholipid-antibodies-in-thrombosis-and-hyperinflammation-during-covid-19-acute-phase